Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Experiment Videos

Imaging tumors with peptide-based radioligands.

T M Behr1, M Gotthardt, A Barth

  • 1Department of Nuclear Medicine of the Philipps-University of Marburg, Germany. tmbehr@mailer.uni-marburg.de

The Quarterly Journal of Nuclear Medicine : Official Publication of the Italian Association of Nuclear Medicine (AIMN) [And] the International Association of Radiopharmacology (IAR)
|July 31, 2001
PubMed
Summary

Regulatory peptides target cancer cells via high-affinity receptors. Peptide-based radiopharmaceuticals offer new diagnostic and therapeutic nuclear oncology tools, with somatostatin analogs already approved for neuroendocrine tumor staging.

Related Concept Videos

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Improved Limit on the Effective Electron Neutrino Mass with the ECHo-1k Experiment.

Physical review letters·2026
Same author

First report of ceftazidime-avibactam resistance in non-mutated bla<sub>KPC-3</sub> K. pneumoniae recovered from patients with no prior treatment, in Latin America.

Diagnostic microbiology and infectious disease·2025
Same author

Ceftazidime-avibactam tolerance and persistence among difficult-to-treat KPC-producing Klebsiella pneumoniae clinical isolates from bloodstream infections.

European journal of clinical microbiology & infectious diseases : official publication of the European Society of Clinical Microbiology·2024
Same author

Micro and nano-scale compartments guide the structural transition of silk protein monomers into silk fibers.

Nature communications·2022
Same author

Protocol for Clinical GLP-1 Receptor PET/CT Imaging with [<sup>68</sup>Ga]Ga-NODAGA-Exendin-4.

Methods in molecular biology (Clifton, N.J.)·2022
Same author

Preoperative PSMA-PET/CT as a predictor of biochemical persistence and early recurrence following radical prostatectomy with lymph node dissection.

Prostate cancer and prostatic diseases·2021

Area of Science:

  • Nuclear Oncology
  • Radiopharmaceutical Chemistry
  • Molecular Imaging

Background:

  • Regulatory peptides exhibit potent, receptor-mediated actions.
  • Overexpression of peptide receptors in neoplasms presents novel molecular targets for cancer diagnosis and therapy.
  • Peptide-based radiopharmaceuticals are emerging as key tools in oncology.

Purpose of the Study:

  • To provide an overview of peptide-based radiopharmaceuticals for cancer diagnosis and therapy.
  • To highlight currently available and clinically advanced peptide radiopharmaceuticals.
  • To discuss the potential of novel peptide radioligands in nuclear oncology.

Main Methods:

  • Review of clinical studies and regulatory approvals of peptide-based radiopharmaceuticals.
  • Analysis of receptor binding characteristics and diagnostic accuracy of various peptide analogs.

Related Experiment Videos

  • Exploration of ongoing research and development in peptide radioligand discovery.

    • Main Results:

    • Somatostatin analogs, like 111In-DTPA-[D-Phe1]-octreotide, are approved for gastroenteropancreatic neuroendocrine tumor staging.
    • Radiolabeled vasoactive intestinal peptide (VIP) visualizes gastrointestinal adenocarcinomas and some neuroendocrine tumors.
    • Radiolabeled gastrin analogs target cholecystokinin B receptor-expressing cancers, including medullary thyroid cancer and small-cell lung cancer.

    Conclusions:

    • Radiolabeled regulatory peptides have significantly advanced nuclear oncology for diagnosis and potential radionuclide therapy.
    • Somatostatin receptor scintigraphy is highly effective for neuroendocrine tumors but limited in other cancers.
    • Ongoing development of diverse peptide radioligands promises expanded clinical applications in oncology.